Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1049-1058

  Vegt, Erik ^a,b   Jong, Marion De ^c   Wetzels, Jack F M ^a   Masereeuw, Rosalinde ^a   Melis, Marleen ^c   Oyen, Wim J G ^a   Gotthardt, Martin ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibody fragment; Kidney; Peptide; PRRT; Radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE LU 177; ACTINIUM 225; CUBILIN; MEGALIN; MERTIATIDE TC 99M; MONOCLONAL ANTIBODY Y 90; PENTETREOTIDE IN 111; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIOPROTECTIVE AGENT; UNCLASSIFIED DRUG; YTTRIUM CARCINOEMBRYONIC ANTIGEN FAB FRAGMENT ANTIBODY Y 90; IMMUNOGLOBULIN FRAGMENT; PEPTIDE;

CHRONIC KIDNEY FAILURE; COMPETITIVE INHIBITION; ENDOCYTOSIS; EXTERNAL BEAM RADIOTHERAPY; GLOMERULUS FILTRATION; HUMAN; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; NEPHROTOXICITY; NONHUMAN; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOTHERAPY; RENAL PROTECTION; REVIEW; ULTRAFILTRATION; ANIMAL; KIDNEY; METABOLISM; RADIATION RESPONSE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNOGLOBULIN FRAGMENTS; KIDNEY; KIDNEY DISEASES; PEPTIDES; RADIOPHARMACEUTICALS;

EID: 77954966119     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.075101     Document Type: Review

References (79)

1. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
2. Van Essen M, Krenning EP, Kam BL, De Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382-393.
3. Behr TM, Behe M, Angerstein C, et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res. 1999;5:3124s-3138s.
4. Gotthardt M, Van Eerd-Vismale J, Oyen WJ, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med. 2007;48:596-601.
5. Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787-794.
6. Brenner BM. Brenner & Rector's The Kidney. Philadelphia, PA: Saunders Elsevier; 2008: sections I.2-I.5, I.7.
7. Russo LM, Sandoval RM, McKee M, et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 2007;71:504-513.
8. Christensen EI, Verroust PJ. Megalin and cubilin, role in proximal tubule function and during development. Pediatr Nephrol. 2002;17:993-999.
9. Ahuja R, Yammani R, Bauer JA, Kalra S, Seetharam S, Seetharam B. Interactions of cubilin with megalin and the product of the amnionless gene (AMN): effect on its stability. Biochem J. 2008;410:301-308.
10. Coudroy G, Gburek J, Kozyraki R, et al. Contribution of cubilin and amnionless to processing and membrane targeting of cubilin-amnionless complex. J Am Soc Nephrol. 2005;16:2330-2337.
11. Trejtnar F, Novy Z, Petrik M, et al. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111. Ann Nucl Med. 2008;22:859-867.
12. Melis M, Krenning EP, Bernard BF, De Visser M, Rolleman E, De Jong M. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. Nucl Med Biol. 2007;34:633-641.
13. 111In-DTPA-octreotide. J Nucl Med. 2005;46:1696-1700.
14. Vegt E, Melis M, Eek A, et al. Megalin plays an important role in the renal uptake of various radiolabelled peptides: studies in megalin-deficient mice [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl 2):231.
15. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936-941.
16. Bates CM, Kegg H, Petrevski C, Grady S. Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules. Kidney Int. 2003;63:53-63.
17. Bhandari S, Watson N, Long E, et al. Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney. J Histochem Cytochem. 2008;56:733-743.
18. Bruno JF, Xu Y, Song J, Berelowitz M. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology. 1993;133:2561-2567.
19. Rolleman EJ, Kooij PP, De Herder WW, Valkema R, Krenning EP, De Jong M. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging. 2007;34:1854-1860.
20. de Weerth A, Jonas L, Schade R, et al. Gastrin/cholecystokinin type B receptors in the kidney: molecular, pharmacological, functional characterization, and localization. Eur J Clin Invest. 1998;28:592-601.
21. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141:120-128.
22. Schwegler JS, Heppelmann B, Mildenberger S, Silbernagl S. Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: a model for proximal tubular protein reabsorption. Pflugers Arch. 1991;418:383-392.
23. Christensen EI, Birn H, Rippe B, Maunsbach AB. Controversies in nephrology: renal albumin handling, facts, and artifacts! Kidney Int. 2007;72:1192-1194.
24. 99mTc-labeled peptides. J Nucl Med. 2000;41:177-182.
25. 111In]DOTATOC in rats: influence of inhibitors of the organic ion transport and diuretics. Eur J Nucl Med Mol Imaging. 2007;34:2129-2134.
26. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
27. Duncan JR, Behr TM, DeNardo SJ. Intracellular fate of radiometals [letter]. J Nucl Med. 1997;38:829.
28. Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nucl Med Biol. 2006;33:101-110.
29. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm. 2002;17:445-464.
30. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
31. Kwekkeboom DJ, De Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
32. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97-109.
33. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med. 2008;49:1884-1899.
34. Krochak RJ, Baker DG. Radiation nephritis: clinical manifestations and pathophysiologic mechanisms. Urology. 1986;27:389-393.
35. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys. 1995;31:1249-1256.
36. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol. 2003;23:486-499.
37. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80:2591-2610.
38. Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with alpha-particleemitting actinium daughters. J Am Soc Nephrol. 2005;16:2677-2689.
39. 99mTc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm. 2007;22:40-49.
40. 177Lu-DOTA (0), Tyr (3)]octreotate in rats. Eur J Nucl Med Mol Imaging. 2007;34:219-227.
41. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847-851.
42. 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847-1856.
43. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm. 2004;19:378-387.
44. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
45. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(suppl 1):99S-106S.
46. 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging. 2008;35:2245-2255.
47. 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol. 2006;33:723-733.
48. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007;48:615-622.
49. 3]-core. Bioconjug Chem. 2008;19:2409-2416.
50. 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28:761-768.
51. 111In-labeled RGD peptide. Nucl Med Biol. 2007;34:29-35.
52. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol. 2004;31:11-19.
53. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003;55:1261-1277.
54. 18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2007;34:1823-1831.
55. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 2007;67:254-261.
56. 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67:2773-2782.
57. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 1997;44:179-188.
58. 188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels. Bioconjug Chem. 2007;18:190-198.
59. Tibben JG, Massuger LF, Boerman OC, et al. Decreased kidney uptake of technetium-99m-labelled Fab' fragments in ovarian carcinoma bearing nude mice using a cleavable chelator. Nucl Med Biol. 1994;21:17-24.
60. Smith-Jones PM, Stolz B, Albert R, Knecht H, Bruns C. Synthesis, biodistribution and renal handling of various chelate-somatostatin conjugates with metabolizable linking groups. Nucl Med Biol. 1997;24:761-769.
61. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer. 1993;67:1437-1439.
62. Pimm MV, Gribben SJ. Prevention of renal tubule re-absorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Eur J Nucl Med. 1994;21:663-665.
63. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55:3825-3834.
64. Rolleman EJ, Valkema R, De Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15.
65. De Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388-1392.
66. Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med. 2005;46:1012-1015.
67. Vegt E, Wetzels JF, Russel FG, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med. 2006;47:432-436.
68. 111In-octreotide in mice and rats. J Nucl Med. 2006;47:528-533.
69. Vegt E, Van Eerd JE, Eek A, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med. 2008;49:1506-1511.
70. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1:466-469.
71. Vegt E, Eek A, Oyen WJ, De Jong M, Gotthardt M, Boerman OC. Albuminderived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2010;37:226-234.
72. Gekle M, Mildenberger S, Freudinger R, Schwerdt G, Silbernagl S. Albumin endocytosis in OK cells: dependence on actin and microtubules and regulation by protein kinases. Am J Physiol. 1997;272:F668-F677.
73. Gekle M, Mildenberger S, Freudinger R, Silbernagl S. Endosomal alkalinization reduces Jmax and Km of albumin receptor-mediated endocytosis in OK cells. Am J Physiol. 1995;268:F899-F906.
74. 111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med. 2004;45:709-713.
75. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur J Cancer. 1996; 32 A (suppl 4): S5-S16.
76. 177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2007;34:763-771.
77. Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys. 2006;64:1503-1512.
78. Moulder JE, Fish BL, Cohen EP. Impact of angiotensin II type 2 receptor blockade on experimental radiation nephropathy. Radiat Res. 2004;161:312-317.
79. Melis M, Bijster M, De Visser M, et al. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging. July 8, 2009 [Epub ahead of print].